Certara, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 9, 2025, discloses a significant leadership transition at Certara, Inc. The filing details the appointment of a new Chief Executive Officer (CEO) and the departure of the incumbent CEO and Board member, effective December 31, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Compensation
- New CEO Appointment: Jon Resnick is appointed as CEO and Class III Board member, effective January 1, 2026.
- Outgoing CEO: Dr. William F. Feehery is departing as CEO and Board member effective December 31, 2025.
- Resnick Compensation Package:
- Base Salary: $750,000 annually.
- Target Bonus: 100% of base salary.
- Make-Whole Equity: $6,500,000 target value (vesting over two years).
- 2025 Long-Term Incentive: $4,000,000 target value (pro-rata).
- 2026 Long-Term Incentive: $8,000,000 target value.
- Equity Structure: 60% performance-vesting stock units, 40% time-vesting restricted stock units.
- Resnick Severance: 1x salary and target bonus (1.5x during change in control protection period) plus accelerated vesting of make-whole equity and pro-rated performance awards upon termination without cause or for good reason.
- Feehery Transition:
- Departure treated as termination without cause under existing agreement.
- Consulting Fee: $20,000 per month for transition services.
- Equity: Pro-rata vesting of May 2025 awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the execution of the leadership transition and the associated compensation obligations.
Key Facts for Investor Verification
- Verify the total equity grant value for Jon Resnick ($18.5 million in initial target value) against peer CEO compensation benchmarks.
- Confirm the specific terms of Dr. Feehery's existing employment agreement referenced in the April 8, 2025 Proxy Statement to understand full severance liabilities.
- Monitor the impact of the leadership change on Certara's strategic direction, given Resnick's background in clinical research services (IQVIA) versus Feehery's tenure.
- Review the vesting conditions for the performance-vesting stock units to understand potential dilution scenarios.